Fierce Pharma March 4, 2024
Kevin Dunleavy

When Pfizer completed its $43 billion buyout of Seagen in December, CEO Albert Bourla said that the New York pharma giant was not just gaining the Seattle biotech’s “golden eggs,” but instead was “acquiring the goose that laid the golden eggs.”

Less than three months later, it’s clear that the goose did not include Seagen’s ambitious manufacturing facility under construction, 13 miles north of its current headquarters.

Pfizer has confirmed a report over the weekend from the Puget Sound Business Journal that it is shutting down construction of the 270,000-square-foot facility in a business park in Everett.

Seagen had embarked on the manufacturing project to reduce its reliance on contract manufacturers for supplies of its commercial and clinical products in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
23andMe: What If …
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients

Share This Article